↓ Skip to main content

Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma

Overview of attention for article published in Frontiers in oncology, September 2019
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma
Published in
Frontiers in oncology, September 2019
DOI 10.3389/fonc.2019.00857
Pubmed ID
Authors

Yao Wang, Jing-jing Li, Hong-jun Ba, Ke-feng Wang, Xi-zhi Wen, Dan-dan Li, Xiao-feng Zhu, Xiao-shi Zhang

Abstract

Immune checkpoint blockade of programmed cell death protein 1 (PD-1) had an impressive long-lasting effect in a portion of advanced-stage melanoma patients, however, this therapy failed to induce responses in several patients; how to increase the objective response rate is very important. Cellular FLICE-inhibitory protein (c-FLIP) could inhibit apoptosis directly at the death-inducing signaling complex of death receptors and is also considered to be the main cause of immune escape. The overexpression of c-FLIPL occurs frequently in melanoma and its expression is associated with the prognosis. We found that the level of c-FLIPL expression was associated with the PD-1 blockade response rate in melanoma patients. Thus, we performed this research to investigate how c-FLIPL regulates immunotherapy in melanoma. We demonstrate that down regulation of c-FLIPL enhances the PD-1 blockade efficacy in B16 melanoma tumor model. Down regulation of c-FLIPL could increase the tumor apoptosis and enhance the antitumor response of T cells in the lymphocyte tumor cells co-culture system. Moreover, knockdown of c-FLIPL could decrease the expression of PD-L1 and recruit more effector T cells in the tumor microenvironment. Our results may provide a new combined therapeutic target for further improving the efficacy of PD-1 blockade in melanoma.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 13%
Student > Master 2 13%
Student > Doctoral Student 1 6%
Student > Bachelor 1 6%
Researcher 1 6%
Other 2 13%
Unknown 7 44%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 19%
Medicine and Dentistry 2 13%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Immunology and Microbiology 1 6%
Agricultural and Biological Sciences 1 6%
Other 0 0%
Unknown 8 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 September 2019.
All research outputs
#20,266,762
of 25,774,185 outputs
Outputs from Frontiers in oncology
#9,495
of 22,796 outputs
Outputs of similar age
#253,320
of 351,688 outputs
Outputs of similar age from Frontiers in oncology
#200
of 391 outputs
Altmetric has tracked 25,774,185 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,796 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,688 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 391 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.